Portal de Periódicos da CAPES

Irbesartan and Emodin on Myocardial Remodeling in Goldblatt Hypertensive Rats

2012; Lippincott Williams & Wilkins; Volume: Publish Ahead of Print; Linguagem: Inglês

10.1097/fjc.0b013e3182650f1c

1533-4023

Can Chen, Liang Zheng, Qiang Chen, Zhi-gen Li,

Apelin-related biomedical research

Objective: Interactions between the renin-angiotensin system (RAS) and transforming growth factor-beta 1 (TGF-β1) have been well documented. The aim was to explore the effect of irbesartan combining with emodin on myocardial remodeling in goldblatt (2K-1C) hypertensive rats. Methods: All 60 Sprague-Dawley rats were randomly divided into five groups: the sham-clipped without any drugs; 2K-1C without any drugs; the 2K-1C with Irbesartan (50mg/kg/day); the 2K-1C with Emodin (80mg/Kg/day); and the 2K-1C with Irbesartan and Emodin together for the last eight weeks of a 12-week period of study. The outcome measures included left ventricular mass index (LVMI), TGF-β1 and Angiotensin II in the left ventricle, mRNA expression of TGF-β1 and connective tissue growth factor (CTGF). Results: Compared with 2K1C group, the 2K1C/Irbesartan group and 2K-1C/Emodin plus Irbesartan group had significantly lower systolic blood pressure and local Angiotensin II(P<0.05). The LVMI in each of the three treatment groups was significantly lower than that in the 2K1C group, especially in the combined group. The mRNA/protein TGF-β1 and the mRNA CTGF of 2K1C/Irbesartan group, 2K1C/Emodin group and 2K-1C/Emodin plus Irbesartan group were significantly decreased compared with 2K-1C group (P<0.05). Conclusions: Irbesartan or Emodin or two drugs together can inhibit myocardial remodeling in renovascular hypertension rats probably by reducing TGF-β1 and CTGF expression. The combination of Irbesartan and Emodin is better than single drug application.